Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 57,300 shares, a decline of 68.0% from the November 30th total of 179,100 shares. Approximately 1.6% of the company’s shares are short sold. Based on an average daily trading volume, of 798,300 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Onconetix, Inc. (NASDAQ:ONCO) by 83.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 562,691 shares of the company’s stock after purchasing an additional 256,612 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 76.04% of Onconetix worth $2,926,000 at the end of the most recent reporting period. 23.89% of the stock is currently owned by institutional investors.

Onconetix Price Performance

Shares of NASDAQ:ONCO traded up $0.04 during midday trading on Friday, reaching $0.39. The company had a trading volume of 3,035,533 shares, compared to its average volume of 337,884. Onconetix has a 52-week low of $0.32 and a 52-week high of $21.40. The company’s 50 day moving average price is $1.69 and its 200 day moving average price is $4.30.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.